Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Lenalidomide versus lenalidomide plus dexamethasone prolonged treatment after second-line lenalidomide plus dexamethasone induction in multiple myeloma
Karolinska Univ Hosp, Sweden.
Karolinska Univ Hosp, Sweden.
Sunderby Hosp, Sweden.
Karolinska Univ Hosp, Sweden; NSU, FL USA.
Show others and affiliations
2018 (English)In: Cancer Medicine, ISSN 2045-7634, E-ISSN 2045-7634, Vol. 7, no 6, p. 2256-2268Article in journal (Refereed) Published
Abstract [en]

Lenalidomide (Len) plus dexamethasone (Dex) is approved for the treatment of relapsed or refractory multiple myeloma (RRMM). It is possible that single-agent Len may be effective as prolonged treatment regimen in RRMM once patients demonstrate an initial response to Len+Dex induction. Patients with RRMM who responded to first-line Len+Dex in an observational study (NCT01430546) received up to 24 cycles of either Len (25mg/day) or Len+Dex (25mg/day and 40mg/week) as prolonged treatment in a subsequent phase 2 clinical trial (NCT01450215). In the observational study (N = 133), median time to response was 1.7 (range 0.6-9.6) months. A complete response to all treatments received in both studies was observed in 11% of patients; very good partial response and partial response rates were 31% and 38%, respectively. Corresponding response rates in the subgroup of patients who did not enter the phase 2 trial (n = 71) were 3%, 18%, and 39%, respectively. Rates of disease progression at 2years in the phase 2 trial were 47% versus 31% for Len versus Len+Dex (P = 0.14). After 36months median follow-up in surviving patients, median time to progression was not reached with Len+Dex and was 24.9months (95% confidence interval 12.5-not calculable, P amp;lt; 0.001) with Len. Three-year OS among the total observational study population was 61% (95% CI, 52-69%). The corresponding rate among patients who entered the phase 2 clinical trial was 73% (95% CI, 60-83%) and was significantly lower among those patients who achieved PR but did not proceed into the phase 2 trial (55%; P = 0.01). In the phase 2 trial, OS was 73% in both treatment arms (P = 0.70). Neutropenia and thrombocytopenia were more common with prolonged (phase 2 trial) versus short-term (observational study) Len administration but remained manageable. Prolonged treatment with Len with or without Dex provides sustained, clinically relevant responses and demonstrates an acceptable safety profile.

Place, publisher, year, edition, pages
WILEY , 2018. Vol. 7, no 6, p. 2256-2268
Keywords [en]
Clinical Trial; Lenalidomide; Multiple Myeloma
National Category
Cancer and Oncology
Identifiers
URN: urn:nbn:se:liu:diva-149531DOI: 10.1002/cam4.1422ISI: 000435771000003PubMedID: 29673108OAI: oai:DiVA.org:liu-149531DiVA, id: diva2:1231062
Note

Funding Agencies|Celgene Corporation; Swedish Cancer Society

Available from: 2018-07-05 Created: 2018-07-05 Last updated: 2018-08-02

Open Access in DiVA

fulltext(355 kB)4 downloads
File information
File name FULLTEXT01.pdfFile size 355 kBChecksum SHA-512
03f86d583dd30a6803d71d24772464ce82474b6bd310f3a1e6de2fc2c4f754c7b0e6cc486ddfe3fd3cb416e90aee67124da75707edf6cf9869e6f3732ea61d37
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Ahlberg, Lucia
By organisation
Department of Clinical and Experimental MedicineFaculty of Medicine and Health SciencesDepartment of Haematology
In the same journal
Cancer Medicine
Cancer and Oncology

Search outside of DiVA

GoogleGoogle Scholar
Total: 4 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 82 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf